Abstract: The present invention generates at least one set of variable odds for at least one payout odds of a game result by an odds processing unit. The number of the variable odds are more than two, and one of the variable odds replaces the corresponding payout odds. The numerical values of parts of the variable odds are lower than the numerical values of the corresponding payout odds. By lowering the numerical values of some of the variable odds, the numerical values of the others of the variable odds can be increased, thereby ensuring that a maximum possible value of the variable odds is attractive enough to players. Additionally, an image synthesis processing unit is provided for generating a synthesized image. By displaying the synthesized image, an immersive experience is enhanced.

Abstract: The present invention relates to a game system capable of determining use time. Any one of a plurality of props is generated by a game result generation unit according to a probability, and a storage unit is caused to record any one of the generated props, or a member management unit is caused to select, according to a consumption record and a given rule, at least one of the plurality of props to be stored into a piece of account data, and the prop recorded in the account data is transferred to the storage unit, the plurality of props each having a specified game effect; moreover, when a control unit determines that a player uses at least one prop recorded in the storage unit, a corresponding specified game effect will be generated, and the used prop is deleted from the storage unit.

Abstract: The present disclosure is directed to individual peptide immunogen constructs targeting portions of the Interleukin-6 (IL-6) protein, compositions containing the constructs, antibodies elicited by the constructs, and methods for making and using the constructs and compositions thereof. The disclosed IL-6 peptide immunogen constructs contain a B cell epitope from IL-6 linked to a heterologous T helper cell (Th) epitope directly or through an optional heterologous spacer. The IL-6 peptide immunogen constructs stimulate the generation of highly specific antibodies directed to the IL-6 receptor (IL-6R) binding site for the prevention and/or treatment of diseases impacted by IL-6 dysregulation.

Abstract: The present invention generates at least one set of variable odds for at least one payout odds of a game result by an odds processing unit. The number of the variable odds are more than two, and one of the variable odds replaces the corresponding payout odds. The numerical values of parts of the variable odds are lower than the numerical values of the corresponding payout odds. By lowering the numerical values of some of the variable odds, the numerical values of the others of the variable odds can be increased, thereby ensuring that a maximum possible value of the variable odds is attractive enough to players. Additionally, an image synthesis processing unit is provided for generating a synthesized image. By displaying the synthesized image, an immersive experience is enhanced.

Abstract: According to the present invention, at least one variable odds set is respectively generated by an odds processing unit for at least one payout odds of a game result, and the at least one variable odds set respectively has at least one variable odds; there totals more than two variable odds, and the at least one variable odds respectively has a selected probability to replace the corresponding payout odds alternatively; moreover, an odds value of a part of all variable odds is lower than that of the corresponding payout odds, and odds values of the other variable odds are to make a change value of a calculated return-to-player percentage satisfy a designated condition, wherein the designated condition may be that the change value of the return-to-player percentage is the minimum.

Abstract: The present disclosure is directed to peptide immunogen constructs targeting portions of Islet Amyloid Polypeptide (IAPP), compositions containing the constructs, antibodies elicited by the constructs, and methods for making and using the constructs and compositions thereof. The disclosed peptide immunogen constructs have more than about 30 amino acids and contain (a) a B cell epitope having about more than about 6 contiguous amino acid residues from the IAPP aggregation prone region of the full-length IAPP protein; (b) a heterologous Th epitope; and (c) an optional heterologous spacer. The disclosed IAPP peptide immunogen constructs stimulate the generation of highly specific antibodies directed IAPP for the prevention and/or treatment of disorders associated with aggregated IAPP.

Abstract: A fusion protein is disclosed. The fusion protein of the invention comprises an Fc fragment of an immunoglobulin G and a bioactive molecule, wherein the Fc is a single chain Fc. The amino acids in the hinge of the Fc is mutated, substituted, or deleted so that the hinge of Fc cannot form disulfide bonds. Methods for producing and using the fusion protein of the invention are also provided.

Abstract: A fusion protein is disclosed. The fusion protein of the invention comprises an Fc fragment of an immunoglobulin G and a bioactive molecule, wherein the Fc is a single chain Fc. The amino acids in the hinge of the Fc is mutated, substituted, or deleted so that the hinge of Fc cannot form disulfide bonds. Methods for producing and using the fusion protein of the invention are also provided.

Abstract: The present disclosure is directed to individual peptide immunogen constructs targeting portions of the Tau protein for the treatment and/or prevention of tauopathies. The present disclosure is also directed to compositions containing the peptide immunogen constructs, methods of making and using the peptide immunogen constructs, and antibodies produced by the peptide immunogen constructs.

Abstract: A fusion protein is disclosed. The fusion protein of the invention comprises an Fc fragment of an immunoglobulin G and a bioactive molecule, wherein the Fc is a single chain Fc. The amino acids in the hinge of the Fc is mutated, substituted, or deleted so that the hinge of Fc cannot form disulfide bonds. Methods for producing and using the fusion protein of the invention are also provided.

Abstract: The present invention relates to the treatment of herpes simplex virus (HSV) infection using an anti-HSV antibody. In particular, the anti-HSV antibody specifically binds to the glycoprotein D (gD) of herpes simplex virus-1 (HSV-1) and herpes simplex virus-2 (HSV-2). The treatment of the present invention is effective against drug-resistant and/or recurrent HSV infection.

Abstract: A fusion protein is disclosed. The fusion protein of the invention comprises an Fc fragment of an immunoglobulin G and a bioactive molecule, wherein the Fc is a single chain Fc. The amino acids in the hinge of the Fc is mutated, substituted, or deleted so that the hinge of Fc cannot form disulfide bonds. Methods for producing and using the fusion protein of the invention are also provided.

Abstract: The present disclosure is directed to individual peptide immunogen constructs targeting portions of the Tau protein for the treatment and/or prevention of tauopathies. The present disclosure is also directed to compositions containing the peptide immunogen constructs, methods of making and using the peptide immunogen constructs, and antibodies produced by the peptide immunogen constructs.

Abstract: The present disclosure is directed to IgE EMPD peptide immunogen constructs and formulations thereof for the treatment of IgE-mediated allergic diseases. The IgE EMPD peptide immunogen constructs have a B cell epitope peptide of more than 20 amino acids, preferably cyclic, linked through an optional spacer to heterologous T helper cell (Th) epitopes derived from pathogen proteins. These peptide immunogen constructs and formulations thereof can stimulate the generation of highly specific antibodies in vaccinated hosts that are directed against the IgE EMPD peptide and are crossreactive with membrane-bound IgE on B lymphocytes committed to IgE secretion. The antibodies induced by the peptide immunogen constructs and formulations thereof in vaccinated hosts can induce apoptosis of IgE-expressing B cells and mediate Antibody Dependent Cellular Cytototoxity (ADCC), resulting in reduction of antigen-specific IgE and total IgE levels in vaccinated hosts to effectively treat IgE-mediated allergic pathology.

Abstract: The present invention is directed to novel promiscuous and artificial T helper cell epitopes (Th epitopes) designed to provide optimum immunogenicity of a target antigenic site. The target antigenic site can include a B cell epitope, a CTL epitope, a peptide hapten, a non-peptide hapten, or any immunologically reactive analogue thereof. The disclosed Th epitopes, when covalently linked to a target antigenic site in a peptide immunogen construct, elicit a strong B cell antibody response or an effector T cell response to the target antigenic site. The Th epitopes are immunosilent on their own, i.e., little, if any, of the antibodies generated by the peptide immunogen constructs will be directed towards the Th epitope, thus allowing a very focused immune response directed to the targeted antigenic site. The promiscuous artificial Th epitopes provide effective and safe peptide immunogens that do not generate inflammatory, anti-self, cell-mediated immune responses following administration.

Abstract: The present disclosure is directed to peptide immunogen constructs targeting portions of Pituitary adenylate cyclase-activating polypeptide (PACAP), compositions containing the constructs, antibodies elicited by the constructs, and methods for making and using the constructs and compositions thereof. The disclosed peptide immunogen constructs have more than about 20 amino acids and contain (a) a B cell epitope having about more than about 9 contiguous amino acid residues from the PACAP receptor binding or activation regions of the full-length PACAP protein; (b) a heterologous Th epitope; and (c) an optional heterologous spacer. The disclosed PACAP peptide immunogen constructs stimulate the generation of highly specific antibodies directed PACAP for the prevention and/or treatment of migraine.

Abstract: The present invention relates to the treatment of IgE mediated diseases using an anti-IgE antibody. In particular, the anti-IgE antibody is a multifunctional antibody against IgE, which neutralizes IgE and inhibits IgE synthesis. Specifically, the treatment of the present invention is effective in providing a rapid and/or sustained suppression of disease symptoms.

Abstract: The present disclosure is directed to a relief system for the effective detection, prevention, and treatment of COVID-19, including (1) serological diagnostic assays for the detection of viral infection and epidemiological surveillance, (2) high-precision, site-directed peptide immunogen constructs for the prevention of infection by SARS-CoV-2, (3) receptor-based antiviral therapies for the treatment of the disease in infected patients, and (4) designer protein vaccine containing S1-RBD-sFc. The disclosed relief system utilizes amino acid sequences from SARS-CoV-2 proteins as well as human receptors for the design and manufacture of optimal SARS-CoV-2 antigenic peptides, peptide immunogen constructs, CHO-derived protein immunogen constructs, long-acting CHO-derived ACE2 proteins, and formulations thereof, as diagnostics, vaccines, and antiviral therapies for the detection, prevention, and treatment of COVID-19.